2025
Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database
Stempel J, Wang R, Lee A, Zeidan A, Ma X, Podoltsev N. Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database. Annals Of Hematology 2025, 104: 2507-2515. PMID: 40102305, PMCID: PMC12052795, DOI: 10.1007/s00277-025-06307-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnemia, AplasticAntilymphocyte SerumBenzoatesBlood TransfusionDatabases, FactualDisease ManagementFemaleHematopoietic Stem Cell TransplantationHumansHydrazinesMaleMiddle AgedPyrazolesRetrospective StudiesUnited StatesYoung AdultConceptsHematopoietic stem cell transplantationAcquired Aplastic AnemiaCalcineurin inhibitorsParoxysmal nocturnal hemoglobinuriaTransfusion-DependentTriple therapyAA patientsAplastic anemiaAllogeneic hematopoietic stem cell transplantationTreated with calcineurin inhibitorsTreated with antithymocyte globulinFlow cytometryInitial management of patientsSevere AA patientsStem cell transplantationBone marrow failureImmune-mediated disordersTreatment initiation delayRetrospective cohort studyManagement of patientsDiagnosis to treatmentNational claims databaseAntithymocyte globulinSibling donorMarrow failure
2019
Healthcare expenses for treatment of acute myeloid leukemia
Bewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12: 641-650. PMID: 31159602, DOI: 10.1080/17474086.2019.1627869.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsCost-Benefit AnalysisHealth Care CostsHematopoietic Stem Cell TransplantationHospitalizationHumansLeukemia, Myeloid, AcuteConceptsHematopoietic stem cell transplantInsurance statusHealthcare costsTreatment approachesAllogeneic hematopoietic stem cell transplantAcute myeloid leukemia (AML) treatmentStem cell transplantTreatment costsDirect healthcare costsInpatient treatment costsPatient insurance statusPersonalized treatment approachesAcute myeloid leukemiaMyeloid leukemia treatmentInfluence health policyIntensive chemotherapyOral therapyCell transplantMain cost driversMyeloid leukemiaNovel agentsMedical outcomesLeukemia treatmentHealthcare resourcesAML
2017
Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation
Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017, 123: 3763-3771. PMID: 28640385, PMCID: PMC5610636, DOI: 10.1002/cncr.30818.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIncremental cost-effectiveness ratioPrice reductionHealth care costsProbabilistic sensitivity analysesMarkov decision-analytic modelCost-effectiveness ratioIndication-specific pricingLife-time costsCare costsAutologous stem cell transplantationDecision analytic modelStandard discountingQALYBrentuximab vedotinHigher health care costsActive surveillancePricingConsolidative settingConsolidation therapyCostSensitivity analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply